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Abstract
Introduction Gene expression profiling of breast carcinomas
has increased our understanding of the heterogeneous biology
of this disease and promises to impact clinical care. The aim of
this study was to evaluate the prognostic value of gene
expression-based classification along with established
prognostic markers and mutation status of the TP53  gene
(tumour protein p53) in a group of breast cancer patients with
long-term (12 to 16 years) follow-up.
Methods The clinical and histopathological parameters of 200
breast cancer patients were studied for their effects on clinical
outcome using univariate/multivariate Cox regression. The
prognostic impact of mutations in the TP53  gene, identified
using temporal temperature gradient gel electrophoresis and
sequencing, was also evaluated. Eighty of the samples were
analyzed for gene expression using 42 K cDNA microarrays and
the patients were assigned to five previously defined molecular
expression groups. The strength of the gene expression based
classification versus standard markers was evaluated by adding
this variable to the Cox regression model used to analyze all
samples.
Results Both univariate and multivariate analysis showed that
TP53 mutation status, tumor size and lymph node status were
the strongest predictors of breast cancer survival for the whole
group of patients. Analyses of the patients with gene expression
data showed that TP53 mutation status, gene expression based
classification, tumor size and lymph node status were significant
predictors of survival. Breast cancer cases in the 'basal-like' and
'ERBB2+' gene expression subgroups had a very high mortality
the first two years, while the 'highly proliferating luminal' cases
developed the disease more slowly, showing highest mortality
after 5 to 8 years.  The TP53 mutation status showed strong
association with the 'basal-like' and 'ERBB2+' subgroups, and
tumors with mutation had a characteristic gene expression
pattern.
Conclusion TP53 mutation status and gene-expression based
groups are important survival markers of breast cancer, and
these molecular markers may provide prognostic information
that complements clinical variables. The study adds experience
and knowledge to an ongoing characterization and classification
of the disease.
Introduction
The evidence suggesting that molecular profiling can refine
breast cancer prognosis are so far promising. From cDNA
microarray analysis of locally advanced breast carcinomas,
Perou and colleagues [1] identified five subgroups based on
their distinct gene expression patterns. The subgroups were
shown to differ with respect to outcome [2], and have also
AI = allelic imbalance; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; ER = estrogen receptor; IHC = immunohistochemistry; LOH = loss 
of heterozygosity; PR = progesterone receptor; RR = relative risk; SAM = significance analysis of microarray; TTGE = temporal temperature gradient 
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been identified in other datasets [3]. van't Veer and colleagues
[4] analyzed node-negative breast cancer patients under the
age of 55 years using DNA microarrays and identified a 'poor
prognosis signature' that predicted short interval to distant
metastasis. A larger set of samples was studied by van de
Vijver and colleagues [5] to confirm the predictive value of this
signature in women under 53 years of age. Other datasets
have been analyzed with similar findings of molecular sub-
groups with different clinical outcomes [6-10]. However, there
are few published studies with a relatively large number of
patients with long-term follow-up.
Several well-established clinical, histopathological and molec-
ular factors are today used as prognostic and predictive mark-
ers of breast cancer. These include patient age, tumor size,
lymph node status, presence of distant metastasis (TNM-
stage; tumor, node, metastasis), histological type, tumor
grade, and estrogen receptor (ER), progesterone receptor
(PR) and ERBB2/HER-2 status. Improvements of prognostic
criteria have been achieved by optimally combining available
markers. The National Cancer Institute [11] and St Gallen
Conference [12] provide adjuvant treatment guidelines based
on these markers. Currently, TNM-staging [13], the Notting-
ham Prognostic Index [14] and Adjuvant Online [15] are the
most commonly used integrated prognostic models.
TP53 mutation status is rarely obtained for routine analysis,
despite accumulating evidence of its prognostic value. Muta-
tions in the TP53 gene have been reported to be present in
more than half of all cancer cases [16]; however, the fre-
quency shows variation between types/subtypes of cancer. In
breast cancer, the frequency of TP53  gene mutations is
approximately 20% to 30%. Acquiring a TP53 mutation has
been suggested to be an early event in breast cancer develop-
ment and it is related to poor prognosis and chemo resistance
[17]. Allelic imbalance (AI) (or loss of heterozygosity (LOH)) at
chromosome location 17p13, where the TP53  gene is
located, has been reported in more than half of breast carcino-
mas [18]. Traditionally, AI is considered as an additional event
eliminating the TP53 tumor suppressor function.
In this study we address the question of whether gene expres-
sion profiles offer better prognostic information in patients with
long-term follow-up. We performed univariate and multivariate
analysis of seven standard markers and TP53 mutation status
for the total group of breast cancer patients. We then analyzed
a large subset of these tumors using cDNA microarrays and
assigned the samples to five previously defined molecular
expression groups. The strength of gene expression-based
classification versus standard markers was evaluated by add-
ing this variable to the Cox regression model used to analyze
all samples. This is the first report that includes both gene
expression groups and TP53 mutation status in a multivariate
analysis.
Materials and methods
Patient material
A series of 212 primary breast cancer cases were studied; 80
of these tumors were analyzed using cDNA microarrays, along
with one normal breast tissue sample collected from breast
reduction surgery. Patient samples were sequentially col-
lected at Ullevål University Hospital from 1990 to 1994 (IRB
approval 350, protocol 75026). The last update of patient
information was done in 2006, providing an observation time
of 12 to 16 years. Patients were followed until death or emi-
gration, and only 12 patients were lost to follow-up. The aver-
age age of the 80 cases analyzed by cDNA microarrays was
65.0 years at time of primary surgery (range 28.2 to 87.7
years), similar to the average age of 64.4 years (range 28.2 to
91.5 years) for the total series. The 80 cases were selected
from the total series based only on sufficient amount of fresh
frozen tissue for microarray analysis. Consequently, a slightly
higher fraction of patients with larger tumor size was observed
in this subcohort. A summary of the clinical and histopatholog-
ical data of the patients is shown in Table 1 (see Additional file
1 for more detailed information). All patients were treated
according to Norwegian national guidelines at the time of diag-
nosis [19] of 200 (full set) and 77 (subset) patients.
Tissue acquisition and histology evaluation
Primary breast carcinoma tissue was snap frozen and stored
at -80°C. Frozen sections stained with hematoxylin/eosin were
reviewed to confirm tumor content, and specimens in which at
least 5% of the cells were carcinoma cells were included in
this study. The majority of samples (80%) analyzed using
microarrays had at least 40% tumor cell content. Sections
from paraffin embedded tissue were re-evaluated by an expe-
rienced breast pathologist (JMN) to classify and grade the car-
cinomas according to the modified Scarff-Bloom-Richardson
method [20] (Table 1).
TP53 and hormone-receptor analysis
DNA was isolated from both peripheral blood cells (leuko-
cytes) and tumor tissue using chloroform/phenol extraction fol-
lowed by ethanol precipitation (Nuclear Acid Extractor 340A;
Applied Biosystems, Foster City, California, USA) according
to standard procedures. TP53 mutation detection in tumor
DNA was performed by prescreening exon 2–11 using tempo-
ral temperature gradient gel electrophoresis (TTGE) [21].
Samples with aberrant migrating bands from TTGE were
sequenced (ABI PRISM™ 377 DNA Sequencer, Applied Bio-
systems) to determine the nature of the mutation. AI analysis
was performed using the ABI 310 capillary electrophoresis on
two different highly polymorphic markers in the TP53 locus,
one located in intron 1 [22] and the other downstream of exon
11 [23]. AI was scored according to a threshold of 0.84 (ratio
between two allele variants in tumor divided by ratio between
two alleles in blood) [24]. At least one of the polymorphic
markers had to show AI to score positive. The ER and PR were
analyzed using both immunohistochemistry (IHC) and bio.Available online http://breast-cancer-research.com/content/9/3/R30
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Table 1
Clinical and histopathological characteristics of cases included in the study
All cases (n = 212) Microarray (n = 80)
Characteristics Number Percent Number Percent
Age (year)
<45 24 11.3 6 7.5
45–55 37 17.5 12 15.0
55–65 38 17.9 20 25.0
65–75 50 23.6 21 26.3
≥75 63 29.7 21 26.3
Gender
Female 211 99.5 79 98.8
Male 1 0.5 1 1.2
Type
Ductal 132 64.4 51 63.8
Lobular 53 25.8 22 27.5
Mucinous 8 3.9 3 3.8
Medullary 4 2.0 0 0
DCIS with microinvasion 1 0.5 1 1.3
Tubulolobular 2 1.0 2 2.5
Other 5 2.4 1a 1.3
Unknown 7 0
Tumor size
pT1 (≤2 cm) 71 34.6 20 26.0
pT2 (>2 ≤5 cm) 112 54.6 44 57.1
pT3 (>5 cm) 15 7.3 8 10.4
pT4 (infiltrating growth) 7 3.4 5 6.5
Unknown 7 3
Node status
pN0 (negative) 95 44.8 33 41.3
pN1 (1–3 positive) 48 22.6 23 28.8
pN2–N3 (≥4 positive) 33 15.6 12 15.0
pNX (Nodes not removed) 36 17.0 12 15.0
Grade
1 19 9.0 6 7.5
2 141 66.5 53 66.3
3 48 22.6 21 26.3
Unknown 4 0
Estrogen receptor
Positive 109 57.7 45 62.5
Negative 80 42.3 27 37.5Breast Cancer Research    Vol 9 No 3    Langerød et al.
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Unknown 23 8
Progesteron receptor
Positive 130 62.8 51 67.1
Negative 77 37.2 25 32.9
Unknown 5 4
TP53 mutation
Mutation 48 23.6 20 25.0
Wild type 155 76.4 60 75.0
Unknown 9 0
Gene expression group
Luminal A 23 28.8
Highly proliferating luminal 15 18.8
Normal-like 20 25.0
Basal-like 12 15.0
ERBB2+ 10 12.5
Adjuvant therapy
Radiation therapy
Yes 60 31.1 25 32.9
No 133 68.9 51 67.1
Unknown 19 4
Chemotherapyb
Yes 27 12.9 11 14.1
No 182 87.1 67 85.9
Unknown 3 2
Hormonal treatmentc
Yes 53 25.1 25 31.6
No 158 74.9 54 68.4
Unknown 1
Recurrence (distant metastisis)
Positive 72 34.1 34 42.5
Negative 139 65.9 46 57.5
Unknown 1 0
Status
Alive 75 37.5 25 32.5
Dead of disease 63 31.5 30 39.0
Dead of other cause 60 30.0 20 26.0
Emmigrated 2 1.0 2 2.6
Unknown 12 3
aRare type with a metaplastic core and spindle cell component. bCMF × 9 (cyclophosphamide, methotrexate, 5-fluorouracil). cTamoxifen; 2 years. 
DCIS, ductal carcinoma in situ.
Table 1 (Continued)
Clinical and histopathological characteristics of cases included in the studyAvailable online http://breast-cancer-research.com/content/9/3/R30
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Patients receiving adjuvant systemic therapy were given nine
courses of CMF (cyclophosphamide, methotrexate, 5-fluorou-
racil) and/or Tamoxifen for two years. Dosage of radiation
given as adjuvant treatment was dependent on indication;
after breast conserving therapy the mammary gland was given
50 Gy (2 Gy × 25). The number of samples entered into the
survival analyses is smaller than 212 (full dataset) and 80 (sub-
set with gene expression data); excluding patients with miss-
ing information or distant metastases at the time of diagnosis
and primary surgery, leaves us with a maximum numberchem-
ical/ligand-binding assay (Abbott Diagnostics, Abbott Park,
Illinois, USA). The results from IHC were used in our data anal-
ysis since that is the current recommended method; however,
in a few cases where IHC had not been performed, results
from a biochemical/ligand binding assay were used.
Microarray experiments and hierarchical clustering
Total RNA was isolated from snap frozen tumor tissue using
TRIzol® solution (Invitrogen™, Carlsbad, California, USA). The
concentration of total RNA was determined using an HP 8453
spectrophotometer (Hewlett Packard) and the integrity of the
RNA was assessed using a 2100 Bioanalyzer (Agilent, Santa
Clara, California, USA). Linear amplification of total RNA was
performed using an optimized protocol previously described
[25]. Amplified tumor RNA was labeled by Cy5 and amplified
RNA from Universal Human Reference total RNA (Strata-
gene®, La Jolla, California, USA) was labeled by Cy3. The
labeling and hybridization of amplified RNA to cDNA microar-
rays, containing more than 42,000 elements, was performed
as previously described [25]. Experimental protocols can be
found at the referred web site [26]. Images of the arrays was
acquired using a Gene Pix 4000B scanner (Axon Instruments,
Sunnyvale, California, USA), and analyzed using Gene Pix Pro
3.0/4.0/4.1 software and by visual inspection. Data were
entered in the Stanford Microarray Database [27], and inten-
sity levels were normalized. Data were filtered for spot quality
and included in the analysis if the pixels within a spot showed
a regression correlation of at least 0.6 or if the signal intensity
of both sample and reference were at least 1.5 over back-
ground. A hierarchical clustering algorithm integrated into the
Stanford Microarray Database was applied to group genes
and samples on the basis of their similarities in expression, and
the results were visualized using TreeView [28] and Java
TreeView [29] software (for analysis software links, see [30]).
Prior to clustering analysis, the data were centered to median
expression of each gene across the dataset. The hierarchical
clustering shown in Figure 1 was performed using previously
described 'intrinsic' genes [3] consisting of 540 clones (rep-
resenting 496 genes corresponding to a single unique Uni-
Gene cluster) whose expression was measurable in at least
70% of the samples. The 'intrinsic' set of genes consisted of
genes with significantly greater variation in expression
between different tumors than between paired samples from
the same tumor, the name reflecting that genes were selected
to optimally identify intrinsic characteristics of breast tumors.
Survival analysis
In the analysis of breast cancer death for all patients and for
patients with gene expression data, we used the Kaplan-Meier
estimator and univariate Cox regression to assess the marginal
effect of each factor (that is, when not correcting for the effect
of other factors). The joint effect of two or more factors was
assessed using multivariate Cox regression. A parsimonious
Cox regression model with only significant factors was
obtained by backwards elimination starting with all factors,
and the final model was checked for all possible two-factor
interactions. The P value for the total effect of a factor was cal-
culated from the (partial) likelihood ratio statistic, while the
Wald test statistic was used to compute the P value for each
level of a multilevel factor. The proportional hazards assump-
tion of Cox regression was checked using the test of Gramb-
sch and Therneau [31] with Kaplan-Meier weights as
implemented in S-PLUS (version 6.1 for Windows. Insightful
Corporation, Seattle, Washington, USA).
Additional statistical analysis
Pearson correlation analysis was used (Microsoft Excel 2000)
to find the correlation between the gene expression profile of
a single sample and five previously defined centroids [3]. The
five centroids were based on a set of tumor samples from
advanced breast cancer cases and represent the average
expression profiles of sample subgroups defined by hierarchi-
cal clustering using genes that showed more similar expres-
sion between two samples from the same tumor than between
any other tumor ('intrinsic' genes). Cross-tabulation and Pear-
son X2-test or Fishers Exact test (when appropriate) were per-
formed using SPSS (version 13.0. SPSS Inc, Chicago, Illinois,
USA) when studying distribution of clinical, histopathological
or molecular genetic parameters. Genes with potential signifi-
cant changes in expression between tumors having TP53
mutations and tumors with wild-type TP53  were identified
using the significance analysis of microarray (SAM) procedure
[32,33]. Data from 27,393 clones whose expression was
measurable in at least 80% of the samples were included in
the analysis.
Results
Gene expression based classification
The 80 breast tumor samples were assigned to five different
subgroups according to their gene expression pattern; luminal
A, highly proliferating luminals, normal-like, basal-like and
ERBB2+. The assignment of tumors into subgroups was
based on hierarchical clustering using the 540 previously
identified 'intrinsic' genes. The resulting dendrogram showed
two main groups of breast tumors (Figure 1); those with high
expression of the ER-related gene cluster and luminal type
characteristics (left branch), and those showing a lower rela-
tive expression of the ER-related cluster (right branch). Further
subdivision of the samples identified five groups similar to
those previously described [2] also in this set of breast tumors.
The correlation between the gene expression profile of eachBreast Cancer Research    Vol 9 No 3    Langerød et al.
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sample and five previously described centroids [2] were calcu-
lated and a scatter chart was made (Figure 2) according to the
order of samples in the dendrogram from hierarchical cluster-
ing (Figure 1). The correlation of each sample to each of the
centroids showed a continuous wave pattern over the sample
set, and visualized how each sample carries elements from dif-
ferent profiles. The luminal A and basal-like breast tumors
showed a pronounced opposite proportional pattern.
In the subsequent Cox regression analysis the breast tumor
samples were assigned to five subgroups based on hierarchi-
cal clustering, combined with the pattern of centroid correla-
tion and fine-tuned by gene expression pattern of
characteristic subgroup markers. It should be emphasized that
the classification method is unsupervised, meaning that the
samples are grouped solely based on the gene expression
data.
Figure 1
Hierarchical clustering using 'intrinsic' genes Hierarchical clustering using 'intrinsic' genes. (a) Five groups were identified, namely the highly proliferating luminal (light blue), luminal A (dark blue), 
normal-like (green), basal-like (red) and ERBB2+ (magenta) groups, which were used in the survival analysis. (b) Hierarchical clustering was per-
formed using 540 clones, representing 496 unique genes from the 'intrinsic' gene list. The individual color of the dendrogram branches reflects the 
correlation with centroids previously described, and tumors with low correlation (<0.2) with a specific subtype are here indicated by gray branches. 
Gene clusters characterizing the five groups (a) involve genes encoding, for example, (c) estrogen receptor (ER), (d) MUC1, (e) cadherin 1 (E-cad-
herin; CDH1), (f) FOXC1 and (g) ERBB2. Since very few genes associated with cell division and proliferation are part of the 'intrinsic' gene list, 
such a cluster was selected from the total list of genes (Additional file 4), clustered and organized according to (h) the 'intrinsic' dendrogram to 
show the difference in proliferation between the two luminal groups. (i) In the same manner, a gene cluster characteristic of the mucinous breast car-
cinomas was made from the total list of genes.Available online http://breast-cancer-research.com/content/9/3/R30
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Survival analysis of all patients
In Table 2 (Univariate analysis) relative risks (hazard ratios)
with 95% confidence intervals (CI) of univariate Cox regres-
sions for all factors considered are shown. P values for testing
the hypothesis of no marginal effect of a factor and its levels
are also given. Tumor size and TP53 status are the two most
significant factors, but lymph node status also has a significant
effect. Patients with TP53 mutations have a breast cancer
death rate that is four to five times higher than for those with-
out mutations. Patients with tumor size T3–T4 have a breast
cancer death rate that is about four times higher than for those
with tumor size T1, while patients with tumor size T2 have a
breast cancer death rate that is about double that of those with
size T1. Patients with four or more positive lymph nodes have
a breast cancer death rate that is about three times higher than
for those with negative lymph nodes. The effect of TP53 status
and tumor size on breast cancer death is also shown in the
Kaplan-Meier plots of Figure 2a. The high number of patients
with the heterogeneous grade 2 probably explains why grade
is not as strong a prognostic marker as expected in this series
of samples. In a multivariate Cox regression model obtained
after elimination of all non-significant factors, the TP53 status,
tumor size and lymph node status are the only significant
remaining factors (Table 2, Multivariate analysis), and their
effects are about the same as in the univariate analysis.
Survival analysis of patients with gene expression data
By performing univariate Cox regressions on the samples
included in the array experiment for all factors considered,
TP53 mutation status, gene expression group, tumor size and
lymph node status were all significant factors for survival
(Table 3, Univariate analysis). The effect of tumor size is some-
what larger than for the analysis of all patients, while the effect
of TP53  status is somewhat smaller. The gene expression
groups have a large effect on survival. The breast cancer death
rates for the highly proliferating luminal, the basal-like and the
ERBB2+ groups are about six times higher than for the luminal
A group, while the breast cancer death rate for the normal-like
Figure 2
Correlation with five centroids Correlation with five centroids. The expression profiles of the samples were correlated with five previously defined centroids (listed with color 
codes). The correlation coefficients were plotted according to the dendrogram in Figure 1 and a continuous and opposite curve-pattern of luminal A 
versus basal-like is evident. The subcluster of luminal samples with the second highest correlation with the luminal B centroid is named 'highly prolif-
erating luminals' in our study.Breast Cancer Research    Vol 9 No 3    Langerød et al.
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group is almost three times that of the luminal A group. As the
assumption of proportional hazards is violated for the highly
proliferating luminals, the relative risk estimate for this group
should be interpreted as an average over the time period con-
sidered. The effect of TP53 mutation status and tumor size on
breast cancer death is also shown in the Kaplan-Meier plots in
Figure 3b, while Figure 3c gives the Kaplan-Meier plot for the
five gene expression groups. The non-proportionality of the
hazard of highly proliferating luminals is clearly seen in the
latter.
In a multivariate Cox regression model obtained after elimina-
tion of all non-significant factors, TP53 mutation status and
lymph node status are the significant remaining factors (Table
3, Multivariate analysis). Gene expression groups and tumor
size were the last factors to be eliminated. TP53 mutation sta-
tus and gene expression group are closely related; 17 of the
20 patients with TP53  mutation are in the basal-like or
ERBB2+ group. This makes it difficult to separate the effect of
TP53 from the effect of the gene expression groups. TP53
mutation and lymph node status are the strongest predictors
of survival in the multivariate analysis, with effects of about the
same size as in the univariate analyses.
Three previously published gene lists as classifiers
Our set of samples was also classified according to three pre-
viously described gene lists [4,8,9]. By clustering the samples
using the genes overlapping with our arrays, the samples were
separated into two main branches in each dendrogram;
predicted to be a good prognosis group and a poor prognosis
group. Although the genes on our arrays did not overlap with
all genes from the respective lists and the respective score
procedure in each paper was not followed, it was interesting
to see whether the gene lists had significance using this sim-
ple approach. In univariate Cox regression analysis two of the
gene lists were significant in predicting breast cancer survival
(15/21 genes: relative risk (RR) 3.70, 95%CI 1.64 to 8.34, P
= 0.0007; 63/76 genes: RR 2.24, 95%CI 1.09–4.61, P =
0.028), while the third was close to being significant despite
the limited number of overlapping genes (26/70 genes: RR
1.99, 95%CI 0.93 to 4.26, P = 0.067). None of the classifiers
were significant when included in multivariate analysis
together with the variables listed in Table 3, a result where the
interpretation should be made according to the previous
stated limitations of our approach.
Table 2
Cox regression analysis for breast cancer death for all patients (n = 179 to 200)
Univariate analysis Multivariate analysis
RR 95 percent CI P RR 95 percent CI P
Age, ≥55 years versus <55 years 0.86 0.51–1.44 0.57
Tumor type (overall effect) 0.14
Lobular (versus ductal) 0.56 0.30–1.06 0.074
Other (versus ductal) 0.66 0.26–1.67 0.38
Tumor size (overall effect) 0.001 0.002
pT2 (versus pT1) 2.22 1.17–4.20 0.014 1.94 0.99–3.82 0.054
pT3–pT4 (versus pT1) 4.17 1.93–9.01 0.0003 4.44 1.95–10.1 0.0004
Lymph node status (overall effect) 0.035 0.027
pN1 (versus pN0) 1.34 0.69–2.62 0.39 1.09 0.54–2.21 0.81
pN2–pN3 (versus pN0) 3.42 1.82–6.41 0.0001 2.73 1.41–5.30 0.003
Othera (versus pN0) 1.69 0.77–3.67 0.19 1.28 0.51–3.20 0.60
Histological grade (overall effect) 0.47
G2 (versus G1) 0.99 0.39–2.50 0.98
G3 (versus G1) 1.43 0.52–3.90 0.49
TP53 mutation (versus wild type) 4.51 2.69–7.56 <0.0001 5.24 3.03–9.07 <0.0001
ER positive (versus negative) 0.72 0.43–1.22 0.23
PR positive (versus negative) 0.82 0.49–1.36 0.44
aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor;P, P 
value for the hypothesis of no effect; RR, relative risk (hazard ratio).Available online http://breast-cancer-research.com/content/9/3/R30
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TP53 status in basal-like and ERBB2+ carcinomas
The most striking characteristic of the basal-like and ERBB2+
subclusters (Figure 4) was that most cases carried a TP53
mutation in their tumor. In the basal-like dendrogram branch
83% (10/12) of the carcinomas harbored a TP53 mutation,
and in the ERBB2+ subcluster the fraction was 70% (7/10). In
the two basal-like tumors with wild-type TP53 (Figure 4) the
mutations may have been missed, or other components of the
pathway may have been affected. The basal-like subcluster
showed a higher correlation between the samples in the den-
drogram compared to other subclusters, as well as higher cor-
relation to the 'basal-like centroid' (Figure 2), which may reflect
the strong impact of a TP53 mutation on the global transcrip-
tion program.
Most of the TP53 mutations detected among the 80 samples
analyzed on the microarray (17/20, 85%) and among the total
series of samples (39/48, 81%) were missense mutations,
which is the type of mutation most frequently found in TP53
[34]. Only three samples outside the basal-like and ERBB2+
clusters were affected with TP53 mutations; two missense
mutations outside the DNA binding domain (codon 113,
codon 138) affecting the highly proliferating luminals and one
frequent missense mutation in the DNA major groove interact-
ing domain (codon 273) affecting the luminal A group. Figure
4 further shows that IHC detected only 50% (10/20) of the
mutations detected by TTGE. Almost half of the samples
analyzed had AI (LOH) of TP53 in their tumor tissue (array: 19/
41, 46%; total: 47/98, 48%), and LOH was strongly
associated with the presence of a TP53 mutation (p < 0.001).
Among the samples analyzed using microarray analysis, the
samples with the highest frequency of AI seemed to cluster in
the outermost three subgroups with the poorest outcome
(basal-like, ERBB2+ and highly proliferating luminal groups).
Interestingly, the highly proliferating luminals showed a high
Table 3
Cox regression analysis for breast cancer death for patients with gene expression data (n = 69 to 77)
Univariate analysis Multivariate analysis
RR 95 percent CI P RR 95 percent CI P
Age, ≥55 years versus <55 years 1.22 0.52–2.84 0.65
Tumor type (overall effect) 0.32
Lobular (versus ductal) 0.65 0.28–1.51 0.31
Other (versus ductal) 0.34 0.05–2.53 0.29
Tumor size (overall effect) 0.014
pT2 (versus pT1) 2.63 0.88–7.86 0.085
pT3–pT4 (versus pT1) 5.27 1.61–17.2 0.006
Lymph node status (overall effect) 0.016 0.004
pN1 (versus pN0) 0.45 0.16–1.26 0.13 0.47 0.17–1.33 0.15
pN2–pN3 (versus pN0) 2.41 0.95–6.08 0.064 3.42 1.29–9.05 0.013
Othera (versus pN0) 2.12 0.75–5.98 0.16 2.70 0.93–7.78 0.067
Histological grade (overall effect) 0.68
G2 (versus G1) 2.20 0.30–16.3 0.44
G3 (versus G1) 2.07 0.25–16.8 0.50
TP53 mutation (versus wild type) 3.46 1.66–7.21 0.002 4.43 2.04–9.64 0.0004
ER positive (versus negative) 0.75 0.35–1.63 0.48
PR positive (versus negative) 0.71 0.33–1.51 0.38
Gene expression (overall effect) 0.006
Highly proliferating luminal (versus luminal A) 6.59 1.79–24.3 0.005
Normal like (versus luminal A) 2.82 0.71–11.3 0.14
Basal like (versus luminal A) 6.93 1.79–26.8 0.005
ERRB2+ (versus luminal A) 5.82 1.30–26.2 0.022
aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor; P, 
P value for the hypothesis of no effect; RR, relative risk (hazard ratio).Breast Cancer Research    Vol 9 No 3    Langerød et al.
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frequency of AI (7/8, 88%) despite a low frequency of muta-
tions in the TP53 gene.
Although the relative expression level of TP53 mRNA meas-
ured using microarrays showed variation between individual
samples, the basal-like and ERBB2+ groups, which had the
most  TP53  mutants, clearly showed the highest mRNA
expression, while the luminal group had intermediate
expression and the normal-like group had a lower expression
(the data were centered to median expression across the data-
set; Figure 4). Two of the three mutated samples falling
outside the basal-like and ERBB2+ groups had mutations that
gave a lower relative expression of TP53 mRNA.
Figure 3
Kaplan-Meier survival curves Kaplan-Meier survival curves. (a) Kaplan-Meier plots of breast cancer survival for all patients. The left panel shows tumor size (T1, T2, T3+T4) and 
the right panel TP53 mutation status (WT, wild type; MUT, mutation). (b) Kaplan-Meier plots of breast cancer survival for patients with gene expres-
sion data; the left panel shows tumor size and the right panel TP53 mutation status. (c) Kaplan-Meier plots of breast cancer survival and recurrence-
free survival according to gene expression group (LA, luminal A; NL, normal-like; ERBB2; BL, basal-like; HPL, highly proliferating luminals). The p 
value from the log rank test (Mantel-Cox) is shown in each panel; 'n' is the number of samples in each group. Deaths due to causes not related to 
breast cancer were treated as censored observations.Available online http://breast-cancer-research.com/content/9/3/R30
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Genes related to mutant TP53
SAM analysis was performed to find the gene expression pat-
tern specific for tumors containing a TP53 mutation. With an
estimated median number of false negatives being zero (delta
slider 1.56 and fold change 2.0), 377 significant clones were
selected when analyzing a set of 27,393 cDNA clones (Addi-
tional file 3). The highly specific gene expression pattern asso-
ciated with TP53 mutation status is illustrated in Figure 5,
where hierarchical clustering of the 80 samples and 80
selected genes (the 40 most significantly upregulated and 40
most downregulated genes of the 377 genes) are shown.
Many genes that showed higher relative expression in carcino-
mas with a TP53 mutation were involved in the cell cycle and
cell proliferation (for example, CCNB2, CDCA5, CENPA, and
UBE2C), while the genes with lower relative expression
showed more diverse functions and were highly associated
with ER status (for example, IRS1, ESR1, DNAL1 and NAT1).
Some of the genes (for example, MYBL2, CDCA8, DNALI1
and DACH1) were also identified recently by Miller and col-
leagues [35] as part of a 32-gene expression signature that
distinguishes  TP53  mutant and wild-type tumors. Further
investigation of the gene expression pattern of different TP53
mutations is needed to understand more about the different
effects they have in breast cancer.
Relationship between clinicopathological markers and 
subgroups
The distribution of clinicopathological markers between the
gene expression subgroups is shown in Figure 4. The sub-
groups that showed the poorest survival had the largest differ-
ence in median age, members of the basal-like and ERBB2+
groups being the youngest (median age 56 years (28 to 75)
and 60 years (47 to 87), respectively) and those of the highly
proliferating luminal group the oldest (median age 75 years
(59 to 82)). Dividing the patients into two equally large groups
(<65 years and ≥65 years) gave a significant skewed distribu-
tion between the five gene expression groups (p = 0.019), but
there was no significant difference when dividing them into
pre- and post-menopausal women (<55 years and ≥55 years)
(Figure 4). Tumor size did not show a statistically significant
skewed distribution between the gene expression groups,
suggesting that the gene expression patterns provide new and
different information compared to this established marker.
Neither was node status associated with any particular gene
expression group.
The histological type and grade, as well as ER and TP53 muta-
tion status all showed a highly significant skewed distribution
between the gene expression groups (p < 0.001; Figure 4).
Figure 4
Clinical, histopathological and molecular characteristics of subgroups Clinical, histopathological and molecular characteristics of subgroups. Dendrogram from hierarchical clustering with distribution of clinical, his-
topathological and molecular markers between the five gene expression groups (highly proliferating luminals, luminal A, normal-like, basal-like, and 
ERBB2+). The color coding is as follows: red, description to the left; gray, unknown; yellow, all other. P values from cross-tabulation and Pearson X2-
test are shown to the right of the panel. Relative expression of mRNA is shown for TP53 (Clone-ID: IMAGE:24415 and IMAGE:236338) and estro-
gen receptor (ER) (IMAGE:725321). The fraction of malignant cells in tumor tissue and histological type are shown in the lower panel: DCIS, ductal 
carcinoma in situ with microinvasion IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MPC, metaplastic carcinoma; MUC, mucinous 
carcinoma; TLC, tubulolobular carcinoma. ILC* is the 'typical lobular' type previously described [36]. IHC, immunohistochemistry; LOH, loss of 
heterozygosity.Breast Cancer Research    Vol 9 No 3    Langerød et al.
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The ERBB2+ and basal-like groups showed the highest frac-
tion of grade 3 tumors (80% and 58%, respectively). Although
carcinomas of the luminal A and highly proliferating luminal
subgroups were mainly grade 2, they differed by the fact that
the luminal A group included 22% of cases with grade 1 and
no grade 3 cases, while the highly proliferating luminal group
included 27% of cases with grade 3 and no grade 1 cases.
Among the luminal samples, 89% were ER positive, while
none of the basal-like and only 30% of the ERBB2+-group
were ER positive. The relative mRNA expression of ER (cen-
tered over the dataset) was compared to protein expression
(IHC) and showed a strong correlation (Figure 4).
Tumor cell content and histological types
Tissue samples with a low fraction of malignant epithelial cells
were included in this study to increase our understanding of
how this may affect a tumor's characteristic gene expression
pattern. Samples with different percentages of malignant
epithelial cells were distributed among all subclasses,
although an over-representation (not statistically significant) of
tumors with low tumor content were seen in the normal-like
subgroups (Figure 4). The invasive lobular carcinomas tended
to have lower tumor content than invasive ductal carcinomas.
Hierarchical clustering of samples with ≥40% tumor cells
results in the same subgroups as when all samples were
included. These results suggest that the gene expression pro-
file of a grossly dissected tumor sample in many cases is not
heavily influenced by a relatively low quantity of malignant
cells, and that tumor stromal cells also may affect the gene
expression profile.
Invasive ductal carcinomas were distributed among all sub-
clusters, but entirely dominated the highly proliferating luminal,
basal-like and ERBB2+ groups (Figure 4). Invasive lobular car-
cinomas were divided into two groups, those clustering with
the normal-like subgroup, previously referred to as 'typical-lob-
ular' [36], and the 'ductal-like lobular' clustering with the two
luminal groups (14/22 and 7/22, respectively). The only lobu-
lar samples clustering on the edge of the basal-like group were
alveolar lobular with pleomorphic areas. Two tubulolobular
carcinomas clustered together in the highly proliferating lumi-
nal subgroup, and three mucinous carcinomas clustered
together in the luminal A subgroup, showing that the pheno-
types distinguished by pathologists are also distinct on a
molecular level. A fourth sample, an invasive ductal carcinoma,
was part of the 'mucinous cluster,' showing a gene expression
Figure 5
Gene expression pattern associated with TP53 mutations status Gene expression pattern associated with TP53 mutations status. Hierarchical clustering of 80 samples using 80 genes selected by significance 
analysis of microarray analysis to be associated with TP53 mutation status. Tumor samples with TP53 mutation are labeled red and wild-type sam-
ples are labeled green (upper dendrogram). Ten genes with the highest correlation in each of the two main branches of the gene cluster (left dendro-
gram) are listed on the right.Available online http://breast-cancer-research.com/content/9/3/R30
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pattern similar to these tumors despite the fact that no typical
mucinous elements in paraffin-embedded or frozen tissue sec-
tions from this patient were seen. The mucinous samples were
all ER positive by IHC, TP53 wild type, ERBB2 negative and
E-cadherin positive. A ductal carcinoma in situ with microinva-
sion and a metaplastic carcinoma clustered in the normal-like
subgroup. The invasive ductal carcinoma sample from a man
(ULL-020) clustered with the highly proliferating luminal group.
Discussion
In the patient series analyzed here both uni- and multivariate
analysis show that TP53  mutation status was a very pro-
nounced prognostic factor. Although some studies have
reported similar findings, others have found a weaker prognos-
tic power for TP53 mutation status [37], which may be due to
the mutation screening approach used (as well as population
differences). The most frequently used method for mutation
screening of the TP53 gene has been IHC, which detects only
mutations that induce protein accumulation, missing
frameshift, nonsense and splice mutations. In this study, sev-
eral of the missense mutations with high levels of mRNA
expression were also missed by IHC (Figure 4), showing the
insufficiency of this technique for mutation screening. The
TTGE/sequencing analysis detected 15% of the TP53 muta-
tions outside exons 5 to 8, supporting the importance of ana-
lyzing the whole gene and not only exons 5 to 8 as many
previous studies have done.
A key issue is whether TP53 mutation status is a prognostic
marker or instead a marker of therapy response only (predic-
tive marker). The results in Table 2 (Multivariate analysis) show
the total effects of tumor size and TP53 status on survival,
effects that may be direct and/or indirect via adjuvant treat-
ment. When including adjuvant therapy in the multivariate anal-
ysis, RR values similar to those in Table 2 were found (TP53,
RR 5.1), indicating that the total effects are mainly a result of
the direct effects, not indirect effects via treatment. Analysis of
patients receiving surgery only (no adjuvant treatment) also
gave similar result (TP53, RR 4.3). Although several studies
have suggested that TP53  mutation status is a predictive
factor [38,39], randomized large-scale studies are needed to
make certain of this. TP53 mutation status may be both a pre-
dictive marker of some treatment regimes as well as a strong
prognostic factor.
The strong correlation of TP53 mutations with the basal-like
subtype is a biologically important finding, and whether it is the
nature of ER-negative basal-like tumors that allows mutational
events in the TP53 gene or that the basal-like gene expression
profile is a consequence only of a TP53 mutation is unresolved
and should stimulate further investigation on the origin of
breast tumor cells. A related question to address in larger
studies is whether the specific gene expression pattern we
found associated with TP53 mutation status was a result of
cellular events directly initiated by mutant TP53 or rather a
result of the dominant cell type (basal-like progenitor or cancer
stem cell) in these tumors. Similar questions apply to the
ERBB2+ subtype, which also shows a strong correlation with
TP53 mutations; in addition, the sequence and impact of the
ERBB2 amplification versus the TP53 mutational event needs
investigation. Sørlie and colleagues [2] reported in their
patient cohort of locally advanced breast cancer a high fre-
quency of TP53 mutations also within the luminal B samples
(highly proliferating luminal cases). A relatively low frequency
of TP53 mutations was found within the highly proliferating
luminals (2/15) in our set of patients with earlier stage tumors.
We propose that TP53 mutations may be an early and causal
event in basal-like tumors whereas in luminal B (highly prolifer-
ating luminals) tumors it may be a consequence of genomic
instability. The strong association found between AI and point
mutations in the TP53 gene in the basal-like and ERBB2+ sam-
ples support the concept of TP53  acting as a tumor
suppressor gene in these tumors [40], while the high fre-
quency of AI despite a low frequency of TP53 mutations in the
highly proliferating luminal group suggests a different mecha-
nism for TP53 in these tumors.
There is a massive interest in defining gene expression profiles
of breast tumors to understand the development and progres-
sion of the disease and to create a novel clinically useful diag-
nostic tool. Many reports are very promising, although the
clinical and genetic heterogeneity of the disease does not
make it straightforward to predict recurrence and outcome in
individuals based on a snapshot of the biological processes in
the individual tumor. Our study aimed to investigate the poten-
tial of gene expression profiling as a prognostic marker in
patients with long term follow-up, and not to create yet another
gene list associated with patient outcome. The extreme
amount of variables (genes) and the relatively low number of
cases and events increases the probability of accidental but
apparently significant findings [41] in microarray analysis. In
this study we have chosen an unsupervised approach for the
classification of samples. The results certainly support the
huge potential of information found in expression patterns, and
the classification is shown to be a statistically highly significant
predictor of survival.
The Kaplan-Meier plot (Figure 3c) illustrates a significant dif-
ference in survival between the different expression groups, as
seen in previous studies [3]. Notice that the two groups with
very poor prognosis had a diverse progression of disease.
Breast cancer cases in both the basal-like and ERBB2+
groups had a very high mortality rate during the first two years,
while the highly proliferating luminal cases developed the dis-
ease more slowly, showing highest mortality after five to eight
years. We were not able to pinpoint any specific heterogeneity
(clinical, histopathological or molecular markers) of the
patients within the highly proliferating luminal cluster, the
group showing non-proportional hazard, and suggest the
curve reflects biological characteristics. Many patients withBreast Cancer Research    Vol 9 No 3    Langerød et al.
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highly proliferating luminal cancer received Tamoxifen treat-
ment for two years, and the poor outcome in this group com-
pared to luminal A patients could be explained by the lack of a
Tamoxifen effect. Alternatively, this anti-estrogen treatment
may temporarily prolong patient survival in this group for the
first years they receive the drug. The different progression
observed in basal-like versus highly proliferating luminal
patients may be consistent with the bimodal mortality rate
reported by Demicheli and colleagues [42].
Different approaches have been used in an attempt to define
clinically relevant groups based on gene expression patterns,
but a consensus on how to do this has not yet been reached.
In our study a classification similar to the one identified by Sør-
lie and colleagues [2] was obtained, supporting the existence
of such subgroups in a broader spectrum of breast tumor
stages. A few samples were, for various reasons, difficult to
categorize. The lack of proliferation genes in the intrinsic gene
list causes a less clear correlation with the luminal B centroid,
but when proliferation genes from the total cluster (Figure 1h)
were included the characteristics of the highly proliferating
luminals (luminal B-like) compared to the luminal A group were
clearly shown. Although the majority of luminal samples were
most highly correlated with the luminal A-centroid, the group
we named highly proliferating luminals is clearly different from
the luminal A group in the scatter chart, having the second
highest correlation with the luminal B-centroid (Figure 2). We
suggest that earlier stages of luminal B (here named highly
proliferating luminals) may have less pronounced expression
profiles than the advanced tumors where the centroids were
defined (our data set versus Sørlie and colleagues [2]). The
small cluster between the normal-like and the basal-like group
shows highest correlation with the ERBB2-centroid, although
this group demonstrates extremely low expression of both the
ERBB2 gene (Figure 1g) and basal-like genes (Figure 1f). The
samples seem more normal-like based on the fact that a nor-
mal breast tissue sample clustered within this group, as well
as showing expression of genes previously identified to char-
acterize normal-like samples. This small cluster illustrates the
difficulties in assigning individual samples to subgroups based
on correlation with centroids alone. The correlation of each
sample with each of the centroids showed a continuous pat-
tern over the sample set, and visualizes how each sample car-
ries elements from different profiles (Figure 2). In Figure 1g,
the ERBB2+ group on the far right side shows high expression
of an ERBB2-related gene cluster and is, therefore, included
in this group, despite the fact that its members also show cor-
relation with the luminal B centroid. It is a matter of choice
which group to assign these samples to. The ERBB2+ group
is defined by a molecular event (overexpression of ERBB2),
whereas the luminal B group is recognized by highly proliferat-
ing ER-positive tumors. Three samples do not show increased
ERBB2 expression, but they are included in the ERBB2+
group based on their clustering. Although these samples
express a low level of ERBB2 on the RNA level, it has been
observed that the protein level (fluorescence in situ hybridiza-
tion analysis) does not always correspond and thus may be
high.
Conclusion
The combination of gene expression groups and clinical/his-
topathological parameters in this study has added more
details and levels of understanding to our current picture of
breast carcinomas. The long follow-up of patients revealed
that the highly proliferating luminal group had an even worse
prognosis than the basal-like and the ERBB2+ groups. The rel-
atively good outcome for the first five years for the highly pro-
liferating luminal group may be explained by the natural history
of these tumors or by use of Tamoxifen. The strong association
found between the basal-like group and TP53 mutations sug-
gests that such mutations may be causal in these tumors,
while  TP53  mutations may be a later event in the highly
proliferating luminal carcinomas. The high frequency of TP53
AI in the highly proliferating luminal group supports a mecha-
nism other than TP53 mutations causing genomic instability in
these tumors, and should be further explored. The characteris-
tic gene expression pattern found in tumors carrying a TP53
mutation also needs further investigation in larger sets of sam-
ples with various mutations included.
Both TP53 mutation status and gene expression subgroups
demonstrated strong prognostic impact, and may add valua-
ble new information that complements the established
prognostic markers. TP53  may help distinguish high risk
tumors in need of treatment from among small, node negative
tumors, which do not currently receive adjuvant treatment (that
is, they are undertreated); on the other hand, it may help avoid
treatment of individuals in patient groups that today may be
overtreated. The choice of treatment may, for example, be influ-
enced by avoiding drugs dependent on TP53-mediated apop-
tosis or, in the future, by using drugs that target and reactivate
TP53. Although gene expression-based subgroups showed
massive prognostic strength, a more robust classification
method is needed for future application in clinical practice.
Development of a new integrated prognostic model that
includes TP53 and gene expression groups could be useful in
the choosing of treatment.
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